Association of Menopausal Status with COVID-19 outcomes: a Propensity Score-Matching Analysis

Xing-Wang Wang  
PLA General Hospital of Southern Theatre Command: People's Liberation Army General Hospital of Southern Theatre Command

Hao Hu  
PLA General Hospital of Southern Theatre Command: People's Liberation Army General Hospital of Southern Theatre Command

Zhi-Yong Xu  
PLA General Hospital of Southern Theatre Command: People's Liberation Army General Hospital of Southern Theatre Command

Gong-Kai Zhang  
PLA General Hospital of Southern Theatre Command: People's Liberation Army General Hospital of Southern Theatre Command

Qing-Hua Yu  
PLA General Hospital of Southern Theatre Command: People's Liberation Army General Hospital of Southern Theatre Command

Hui-Lan Yang (huilany88@vip.163.com)  
PLA General Hospital of Southern Theatre Command: People's Liberation Army General Hospital of Southern Theatre Command

Ji-Hua Zheng (zjz19930901@163.com)  
People's Liberation Army General Hospital of Southern Theatre Command  
https://orcid.org/0000-0001-9210-4971

Research

Keywords: COVID-19, menopause status, mortality, disease severity, propensity score–matching

DOI: https://doi.org/10.21203/rs.3.rs-111926/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Despite the growing number of studies on the Coronavirus Disease-19 (COVID-19), little is known about the association of menopausal status with COVID-19 outcomes.

Materials and methods: In this retrospective study, we included 336 COVID-19 in-patients between February 15, 2020 and April 30, 2020 at the Taikang Tongji Hospital (Wuhan), China. Electronic medical records, including patient demographics, laboratory results, and chest computed tomography (CT) images were reviewed.

Results: In total, 300 patients with complete clinical outcomes were included for analysis. The mean age was 65.3 years and most patients were women (n=167, 55.7%). Over 50% of patients presented with comorbidities, with hypertension (63.5%) being the most common comorbidity. After propensity-score matching, results showed that men had significantly higher odds than premenopausal women for developing severe disease type (23.7% vs. 0%, OR 17.12, 95% CI 1.00–293.60; \( p =0.003 \)) and bilateral lung infiltration (86.1% vs. 64.7%, OR 3.39, 95% CI 1.08–10.64; \( p = 0.04 \)), but not for mortality (2.0% vs. 0%, OR 0.88, 95% CI 0.04–19.12, \( p =1.00 \)). However, non-significant difference was observed among men and post-menopause women in the percentage of severe disease type (32.7% vs. 41.7%, OR 0.68, 95% CI 0.37–1.24, \( p =0.21 \)) and bilateral lung infiltration (86.1% vs. 91.7%, OR 0.56, 95% CI 0.22–1.47, \( p =0.24 \)), mortality (2.0% vs. 6.0%, OR 0.32, 95% CI 0.06–1.69, \( p =0.25 \)).

Conclusions: Men had higher disease severity than premenopausal women, while the differences disappeared between postmenopausal women and men. These findings support aggressive treatment for the poor-prognosis of postmenopausal women in clinical practice.

Introduction

Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to severe illness and death all over the world [1-4]. As of September 13, 2020, there were over 28 million confirmed cases and over 917,000 related deaths reported worldwide [5]. This pandemic poses a serious challenge to the global health system and world economy.

With the increasing studies on COVID-19, the association of sex differences (i.e. between men and women) with the clinical outcomes started to be reported. Sex differences in the innate and adaptive immune systems leads to differences in the susceptibility and response to SARS-CoV-2, as well as incidence and disease severity [6]. However, the differences in COVID-19 outcomes between men and women are inconsistent [1, 4, 7, 8], emphasizing the need to understand the sex-related COVID-19 outcomes.

Biological sex plays a multidimensional role in COVID-19 outcomes, including complex interactions based on sex chromosome complement, reproductive tissues, and the concentration of sex steroid hormones (estrogen, progesterone, and testosterone) [9]. Despite several studies investigating common
susceptibility factors (older age, sex, comorbidities) to virus infection [10, 11], little is known about the association of menopause status (i.e., pre-menopause and post-menopause) with clinical outcomes of hospitalized patients with COVID-19. As previously reported [12], postmenopausal women showed a significant change in the concentration of plasma sex hormones (e.g. estrogen and progesterone depletion) compared with premenopausal women. In addition, estrogen and/or progesterone may regulate the innate and adaptive immune response [13, 14]. However, whether premenopausal and postmenopausal women exhibited different COVID-19 outcomes remains unclear.

In the present study, we conducted a retrospective analysis, using the propensity score–matching method to minimize selection bias and control potential confounding factors, to separately compare COVID-19 outcomes of hospitalized premenopausal women, postmenopausal women, and men.

**Materials And Methods**

**Study Design and Patients Selection**

As shown in Supplementary Figure 1, this retrospective study included 336 consecutive adult patients admitted with COVID-19—confirmed by reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 infection—between February 15, 2020 and April 30, 2020 at Taikang Tongji Hospital (Wuhan, China), that was a temporarily designated hospital for treating patients with COVID-19 [15]. After initial screening, 36 of the 336 patients were excluded due to missing data. Thus, we estimated the sex-differences outcomes in the remaining 300 patients. This study was approved by the Ethics Committee of General Hospital of Southern Theatre Command of PLA. Because of the retrospective design and anonymous data used in the study, written informed consent was not obtained.

**Propensity Score-Matching**

As previously reported [16], propensity score-matching can balance the treatment and control groups based on baseline covariates to minimize the bias factors and control potential confounding factors. Therefore, we performed propensity score-matching at a ratio of 1:1 nearest-neighbor matching algorithm to adjust for age, body mass index (BMI), comorbidities (hypertension, diabetes, cerebrovascular disease, chronic obstructive pulmonary disease, coronary heart disease, and cancer), treatment (corticosteroids, arbidol, and interferon), and laboratory results (lactic dehydrogenase, lymphocyte, and C-reactive protein). Finally, a well-balanced cohort of 101 paired patients (men and women) was analyzed (Table 1).

**Data Collection**

We reviewed the medical records and extracted the following data: age, sex (including menopause status for women), body mass index (BMI), comorbidities (hypertension, diabetes, cerebrovascular disease, chronic obstructive pulmonary disease, coronary heart disease and cancer), treatment (corticosteroids, arbidol, and interferon), laboratory results (lactic dehydrogenase, lymphocyte and C-reactive protein), and chest computed tomography (CT) images. According to the criteria of the Working Group on Obesity in
China [17], we categorized BMI (calculated as weight in kilograms divided by height in meters squared) into three groups: underweight and normal weight, BMI < 24 kg/m²; overweight, 24 ≤ BMI < 28 kg/m², and; obese, BMI ≥ 28 kg/m². 

**Definition and Outcomes**

Menopause is defined retrospectively as the cessation of spontaneous menstruation for 12 months [18]. The primary outcomes were disease severity, mortality, and chest CT imaging features. As previously reported [1], COVID-19 disease severity was divided into severe or non-severe. Severe disease should meet any of the following criteria: (a) respiratory rate ≥ 30 breaths per min; (b) oxygen saturation ≤ 93% in a resting state; (c) ratio of arterial oxygen partial pressure and oxygen concentration ≤ 300 mmHg, and; (d) progression of more than half of lesions in lung imaging within 1–2 days. Chest CT imaging features were classified as unilateral lung infiltration or bilateral lung infiltration based on a CT diagnosis report provided by experienced thoracic radiologists in the electronic medical records.

**Statistical Analysis and Subgroup Analysis**

To investigate the impact of menopausal status on COVID-19 outcomes, we compared clinical outcomes in three groups of well-balanced and case-matched COVID-19 patients: men, premenopausal women, and postmenopausal women. All analyses were conducted using SPSS (version 22.0, IBM SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6.07 (GraphPad Software, Inc., La Jolla, CA, USA). Continuous and categorical variables were presented as mean (standard deviation) and number (%), respectively. Continuous variables were compared using unpaired Student’s t-test. Categorical variables were compared using Chi-square test or Fisher’s exact test, if appropriate. All statistical significance was two-sided and set at $p$-value less than 0.05.

**Results**

**Study Cohort Characteristics Before and After Score-Matching Analysis**

As of April 30, 2020, we collected the medical records of 336 patients hospitalized with COVID-19. Of these patients, 36 patients were excluded due to missing data: two patients without complete outcomes, 11 without data of blood routine examination, 15 without data of lactic dehydrogenase, and 8 without height and/or weight data. Thus, 300 patients (89.3%, 300/336) with complete clinical information were enrolled in our study (Supplementary Figure 1). The basic characteristics of the study population before and after score-matching analysis are presented in Table 1. Before score-matching analysis, the mean age was 65.3 ±14.6 years, ranging from 14 years to 95 years, and most patients were female (n=167, 55.7%). Comorbidities were present in in over 50% of patients, with hypertension (63.5%) being the most common comorbidity, followed by diabetes (19.0%) and coronary heart disease (19.0%). Several baseline characteristics differed significantly between the men and women group (Table 1), such as the percentages of patients ≥ 65 years ($p=0.004$), patients treated with corticosteroids ($p=0.02$) and arbidol ($p=0.03$). After propensity score-matching analysis, 202 patients were identified and the baseline...
characteristics of the patients were well balanced between groups (Table 1). A total of 68 patients developed severe disease type (33.7%), of whom 51.5% (35/68) were women. CT chest imaging revealed bilateral lung infiltration in most patients (86.6%, 175/202). There were 7 in-hospital deaths (3.5%), of whom 5 (71.4%, 5/7) were women.

**Clinical Outcomes Between Men and Women**

As shown in Figure 1, the percentage of severe disease type (32.7% vs. 34.7%, odds ratio [OR] 0.92, 95% CI 0.51–1.64, \( p=0.77 \); Figure 1A) and bilateral lung infiltration (86.1% vs. 87.1%, OR 0.92, 95% CI 0.41–2.07, \( p=0.84 \); Figure 1C) were similar between men and women. Notably, although men showed a lower mortality rate than women, this difference was not statistically significant (2.0% vs. 5.0%, OR 0.39, 95% CI 0.07–2.05, \( p=0.44 \); Figure 1B).

**Association of Menopausal Status with COVID-19 Outcomes**

The women group was divided into two subgroups based on menopausal status: the premenopausal group and the postmenopausal group. Compared with premenopausal women, men displayed a significantly higher percentage of severe disease type (23.7% vs. 0.0%, OR 17.12, 95% CI 1.00–293.60, \( p=0.003 \); Figure 2A) and bilateral lung infiltration (86.1% vs. 64.7%, OR 3.39, 95% CI 1.08–10.64, \( p=0.04 \); Figure 2C). However, no significant difference in mortality was observed between the two groups (2.0% vs. 0%, OR 0.88, 95% CI 0.04–19.12, \( p=1.00 \); Figure 2B). In contrast, there was no difference in the percentage of severe disease type (32.7% vs. 41.7%, OR 0.68, 95% CI 0.37–1.24, \( p=0.21 \); Figure 3A) and bilateral lung infiltration (86.1% vs. 91.7%, OR 0.56, 95% CI 0.22–1.47, \( p=0.24 \); Figure 3C) between men and postmenopausal women. However, mortality still did not differ between the two groups (2.0% vs. 6.0%, OR 0.32, 95% CI 0.06–1.69, \( p=0.25 \); Figure 3B).

**Discussion**

Little is known about the relationship between menopausal status and COVID-19 outcomes. To our knowledge, this is the first study comparing COVID-19 outcomes of premenopausal women and postmenopausal women with men for in hospitalized patients based on well-conducted propensity score-matching analysis. In this study, we observed that men were significantly more likely to experience severe disease compared to premenopausal women; however, the odds of experiencing mortality was not significantly different between the two groups. Notably, the odds of experiencing severe disease and mortality were not significantly different between men and postmenopausal women. This data suggests that menopausal status bias exists in patients with COVID-19. Considering the serious health consequences and tremendous economic impacts caused by COVID-19, our findings may be useful for guiding clinicians to deploy aggressive treatment against the poor-prognosis of postmenopausal women in clinical practice.

A recent retrospective study [7] reported that men were significantly associated with a higher intensive care unit (ICU) admission rate compared with women in Metropolitan Detroit. However, in this study the
patients in the ICU were more likely to present with severe COVID-19 and be of older age (age >60 years) compared with patients in the general wards. In a number of studies, the poor outcomes of older patients have been associated with reduced immune system status [19-22]. Additionally, the high proportion of cases and hospitalizations observed in women might negatively affect family structure and increase health risks, and resulted in a worse prognostic profile. Jin et al [8] also reported a high risk of severe outcomes among men with COVID-19 in China. However, this study included only a case series of 43 patients for severity analysis due to the unavailability of detailed patient information in the public data set. In addition, this smaller study for mortality analysis analyzed a heterogeneous data set. Previously published meta-analyses [23, 24] demonstrated that men had a higher prevalence of COVID-19, a higher risk of developing severe disease, and higher mortality than women. However, the clinical characteristics between the groups were unbalanced, which may have biased the results. Omar et al [25] included 88 adult patients in Eastern Sudan and indicated that there was no significant difference in the death rate between men and women. However, this analysis was based on a small number of heterogeneous patients. Moreover, this study did not adjust for potential confounding factors such as age, BMI, comorbidities, or treatment, which were well balanced in our study by using propensity score-matching analysis. Collectively, these studies may be biased in a number of ways. Firstly, they comprise relatively small sample sizes, which may result in an elevated false discovery rate or even false-positive results [26]. Secondly, the clinical characteristics between the groups were unadjusted, which was easily biased. Besides, clinical outcomes based on menopausal status were not examined in their studies. An additional limitation shared by the previous studies is that information on patient BMI and treatment medication, both known prognostic factors for COVID-19 outcomes, were not available. By contrast, in our study, BMI and treatment medication were well balanced between male and female patients. In our study, which is based on a relatively large sample size, accurate baseline and complete clinical outcome data, and propensity score-matching analysis of patients’ clinical characteristics, we demonstrated that men had a significantly higher risk of developing severe COVID-19 disease than premenopausal women, but not postmenopausal women. Our results may be explained in part by the changing biochemistry due to menopause. First, loss of ovarian function at menopause and the resulting change in the concentration of sex hormones may contribute to the increased risk of COVID-19. For example, premenopausal women have higher levels of estrogen postmenopausal women of the same age [12]. Given that estrogen plays a crucial role in protecting female mice from SARS-CoV infection, and that ovariectomy or estrogen receptor blockage increases the susceptibility to infection and mortality [27], our results may be explained in part by the protective effect of estrogen against COVID-19 in premenopausal women. On the one hand, cytokine storm syndrome—an aberrant immune response to SARS-CoV-2—is one of the main reasons for the morbidity and mortality in COVID-19 [28]. In addition to its immunomodulatory effects, estrogen modulates the expression of Th1 and Th2 cytokines, deactivates excessive inflammatory processes, and restores homeostatic conditions, thus potentially inhibiting cytokine storm syndrome from occurring in women [13, 29]. On the other hand, in vitro data suggest that estrogen might exert direct antiviral activity on SARS-CoV-2 by downregulating the expression of angiotensin converting enzyme 2 (ACE2) mRNA in bronchial epithelial cells, which has been proven to be the major receptor responsible for mediating virus entry into cells [30]. In support of this, the data from SARS-CoV-2 indicate that the use of estrogen therapy...
could be effective in the fight against COVID-19 [27, 31], further emphasizing the necessity of further research in patients treated with these agents. However, whether the protective effects of estrogen on COVID-19 outcomes is dose-dependent is unclear due to the unavailability of the concentration of sex hormones in the retrospective study. Second, Honour et al reported that postmenopausal women have higher concentrations of cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and C-reactive protein, compared with premenopausal women [12]. Zhu et al indicated that high levels of IL-6 and C-reactive protein were independent risk factors of COVID-19 severity [32]. Akbari et al also demonstrated that group of patients with severe COVID-19 had a significant increase in the TNF-α, IL-6, and C-reactive protein compared to the non-severe group, suggesting that these cytokines were closely associated with COVID-19 severity [33]. Hence, an increase in the concentrations of these cytokines in postmenopausal women may contribute to our findings, further emphasizing a need for increased awareness and careful monitoring of postmenopausal women. Notably, our analysis found that the mortality did not differ between the groups of men and premenopausal women, partly due to the low mortality rate observed in the limited number of premenopausal patients analyzed. However, these results should be interpreted cautiously due to the wide confidence intervals for the calculated ORs in those patients.

The present study may suffer from several limitations. First, because of the rapid emergency of the COVID-19 outbreak, our study was a retrospective analysis and not all laboratory tests were performed in all patients. Although clinical characteristics and laboratory tests were generally balanced between the men and women groups, several potentially confounding factors may not have been included and their role might be underestimated in our study. Second, the concentrations of sex hormones were unavailable due to the retrospective study design. As more data becomes available, further investigation will be required to confirm our findings. Third, the results of several clinical characteristics in our study may differ from studies in western cultures, possibly restricting the generalizability of the results. For example, previous studies mentioned that obesity (BMI>30) was an important factor for COVID-19 outcomes; there were few individuals who were obese in the present study, compared to a significantly higher number in western cultures. Finally, the separate long-term effects of COVID-19 remains unclear and needs to be evaluated further.

**Perspective and significance**

Menopausal status can influence COVID-19 outcomes. Premenopausal women display lower disease severity than men, while postmenopausal women do not. Physicians should take consideration of whether women are pre- or postmenopausal when they present with COVID-19 infections, and be most aggressive in their treatment of postmenopausal women similar to their treatment of men. Further mechanistic insights are needed to determine whether menopausal status has a specific impact on the immune system response to SARS-CoV-2.

**Declarations**
Ethics declarations

Availability of data and material

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics approval and consent to participate

The studies involving human participants were reviewed and approved by the Ethics Committee of General Hospital of Southern Theatre Command of PLA. Because of the retrospective design and anonymous data used in the study, written informed consent was not obtained.

Author Contributions

X-W W and H H: wrote the manuscript, data calculation, and data assessment. Z-Y X, G-K Z, and Q-H Y: data assessment and substantial contribution to the discussion. H-L Y and J-H Z: project design, data interpretation, and substantial contribution to the discussion. All authors contributed to the article and approved the submitted version.

Acknowledgements

The authors thank AiMi Academic Services (www.aimieditor.com) for English language editing and review services. We also would like to thank the reviewers whose comments and suggestions greatly improved this manuscript.

Competing interests

None

Funding

None

Consent for publication

Not applicable

References

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, 395(10229):1054-1062.

2. Jones DS: History in a Crisis - Lessons for Covid-19. N Engl J Med 2020, 382(18):1681-1683.
3. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G: **Virology, Epidemiology, Pathogenesis, and Control of COVID-19.** *Viruses* 2020, **12**(4).

4. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C *et al.* **Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.** *JAMA internal medicine* 2020, **180**(7):934-943.

5. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report. Accessed at 16 September 2020.

6. Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H: **Racial and Gender-Based Differences in COVID-19.** *Front Public Health* 2020, **8**:418.

7. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, Demertzis Z, Hanna Z, Failla A, Dagher C *et al.* **Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit.** *JAMA network open* 2020, **3**(6):e2012270.

8. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, Liu S, Yang JK: **Gender Differences in Patients With COVID-19: Focus on Severity and Mortality.** *Front Public Health* 2020, **8**:152.

9. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL: **Considering how biological sex impacts immune responses and COVID-19 outcomes.** *Nat Rev Immunol* 2020, **20**(7):442-447.

10. Tian J, Yuan X, Xiao J, Zhong Q, Yang C, Liu B, Cai Y, Lu Z, Wang J, Wang Y *et al.* **Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.** *Lancet Oncol* 2020, **21**(7):893-903.

11. Kang SJ, Jung SI: **Age-Related Morbidity and Mortality among Patients with COVID-19.** *Infect Chemother* 2020, **52**(2):154-164.

12. Honour JW: **Biochemistry of the menopause.** *Ann Clin Biochem* 2018, **55**(1):18-33.

13. Beagley KW, Gockel CM: **Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone.** *FEMS Immunol Med Microbiol* 2003, **38**(1):13-22.

14. Ortona E, Pierdominici M, Rider V: **Editorial: Sex Hormones and Gender Differences in Immune Responses.** *Front Immunol* 2019, **10**:1076.

15. ChinaDaily: **Two more military-led hospitals put into use in virus-hit Wuhan.** 19.Feb.

16. Morgan CJ: **Reducing bias using propensity score matching.** *J Nucl Cardiol* 2018, **25**(2):404-406.

17. Ji CY, Chen TJ: **Empirical changes in the prevalence of overweight and obesity among Chinese students from 1985 to 2010 and corresponding preventive strategies.** *Biomed Environ Sci* 2013, **26**(1):1-12.

18. Takahashi TA, Johnson KM: **Menopause.** *Med Clin North Am* 2015, **99**(3):521-534.

19. Pietrobon AJ, Teixeira FME, Sato MN: **Immunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People.** *Frontiers in immunology* 2020, **11**:579220.

20. Zimmermann P, Curtis N: **Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections.** *Archives of disease in childhood* 2020.
21. de la Rica R, Borges M, Gonzalez-Freire M: COVID-19: In the Eye of the Cytokine Storm. *Frontiers in immunology* 2020, 11:558898.

22. Nikolich-Zugich J: The twilight of immunity: emerging concepts in aging of the immune system. *Nature immunology* 2018, 19(1):10-19.

23. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, Zhang HY, Sun W, Wang Y: COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol* 2020, 92(6):577-583.

24. Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA: Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. *BMJ Open* 2020, 10(10):e040129.

25. Omar SM, Musa IR, Salah SE, Elnur MM, Al-Wutayd O, Adam I: High Mortality Rate in Adult COVID-19 Inpatients in Eastern Sudan: A Retrospective Study. *Journal of multidisciplinary healthcare* 2020, 13:1887-1893.

26. Liu X, Guo CY, Wen XM, Kuang YK, Zhu Q, Hu H: Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis. *Int J Cancer* 2020, 147(1):116-127.

27. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S: Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol* 2017, 198(10):4046-4053.

28. Jose RJ, Manuel A: COVID-19 cytokine storm: the interplay between inflammation and coagulation. *The Lancet Respiratory medicine* 2020, 8(6):e46-e47.

29. Moulton VR: Sex Hormones in Acquired Immunity and Autoimmune Disease. *Front Immunol* 2018, 9:2279.

30. Cattrini C, Bersanelli M, Latocca MM, Conte B, Vallome G, Boccardo F: Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer. *Cancers (Basel)* 2020, 12(8).

31. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell discovery* 2020, 6:14.

32. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, Gao G: Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. *Int J Infect Dis* 2020, 95:332-339.

33. Akbari H, Tabrizi R, Lankarani KB, Aria H, Vakili S, Asadian F, Noroozi S, Keshavarz P, Faramarz S: The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *Life Sci* 2020, 258:118167.

Table
### Table 1 Baseline characteristics before and after matching cohorts

| Characteristics                     | No.(%) before PSM | No.(%) after PSM | P value |
|-------------------------------------|-------------------|------------------|---------|
|                                     | Total (N=133)     | Men (N=167)      |         |
| **Age (mean± SD), years**           | 65.3±14.6         | 65.6±14.6        | 65.0±14.7 | 0.74 |
|                                     | 65.3±14.8         | 65.2±14.9        | 65.4±14.7 | 0.92 |
| **Age ≥ 65**                        | 148 (49.3)        | 78 (58.6)        | 70 (41.9) | 0.004* |
| **Age<65**                          | 152 (50.7)        | 55 (41.4)        | 97 (58.1) |         |
|                                     | 83 (41.1)         | 41 (40.6)        | 42 (41.6) | 0.89 |
| **BMI**                             |                   |                  |         |
| **Under and normal weight**         | 220 (73.3)        | 93 (69.9)        | 127 (76.0) | 0.47 |
| **Overweight**                      | 69 (23.0)         | 35 (26.3)        | 34 (20.4) |         |
| **Obese**                           | 11 (3.7)          | 5 (3.8)          | 6 (3.6) |         |
|                                     | 146 (72.2)        | 71 (70.3)        | 75 (74.2) | 0.3 |
| **Comorbidities**                   |                   |                  |         |
| **Hypertension**                    | 196 (65.3)        | 94 (70.7)        | 102 (61.1) | 0.08 |
| **Diabetes**                        | 57 (19.0)         | 26 (19.5)        | 31 (18.6) | 0.83 |
| **Cancer**                          | 8 (26.7)          | 5 (3.8)          | 3 (1.8) | 0.29 |
| **Coronary heart disease**          | 57 (19.0)         | 24 (18.0)        | 33 (19.8) | 0.71 |
| **COPD**                            | 39 (13.0)         | 24 (15.1)        | 15 (38.5) | 0.02* |
| **Cerebrovascular disease**         | 30 (10.0)         | 14 (46.7)        | 16 (53.3) | 0.79 |
| **Treated with corticosteroids**    |                   |                  |         |
| **Yes**                             | 19 (6.3)          | 13 (9.8)         | 6 (3.6) | 0.03* |
| **No**                              | 281 (93.7)        | 120 (90.2)       | 161 (96.4) |         |
| **Treated with interferon**         |                   |                  |         |
| **Yes**                             | 35 (11.7)         | 16 (12.0)        | 19 (11.4) | 0.86 |
| **No**                              | 265 (88.3)        | 117 (88.0)       | 148 (88.6) |         |
| **Treated with arbidol**            |                   |                  |         |
| **Yes**                             | 153 (51.0)        | 77 (57.9)        | 76 (45.5) | 0.03* |
| **No**                              | 147 (49.0)        | 56 (42.1)        | 91 (54.5) |         |
| **Lactic dehydrogenase**            |                   |                  |         |
| **Abnormal**                        | 38 (12.7)         | 20 (15.0)        | 18 (10.8) | 0.27 |
| **Normal**                          | 262 (87.3)        | 113 (85.0)       | 149 (89.2) |         |
| **Lymphocyte**                      |                   |                  |         |
| **Abnormal**                        | 207 (69.0)        | 81 (60.9)        | 126 (75.4) | 0.007* |
| **Normal**                          | 93 (31.0)         | 52 (39.1)        | 41 (24.6) |         |
| **C-reaction protein**              |                   |                  |         |
| **Abnormal**                        | 70 (23.3)         | 41 (30.8)        | 29 (17.4) | 0.006* |
| **Normal**                          | 230 (76.7)        | 92 (69.2)        | 138 (82.6) |         |
| **Abbreviations:** PSM, propensity score matching; SD, standard deviation; COPD, chronic obstructive pulmonary disease. |
| *Significant at P < 0.05*            |